Tenaya Therapeutics Inc (TNYA) Stock Analysis
Verdict: WATCH (do not buy)
Strong clinical pipeline and cash position are negated by chronic insider selling and a truncated 18-month liquidity runway.
Investment score: 42/100
Analysis as of
Is Tenaya Therapeutics Inc stock worth reviewing? AI model thesis
Tenaya offers high-optionality on gene therapy for heart disease but faces binary clinical risks and a ticking clock on cash reserves.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Tenaya Therapeutics Inc opportunities and risks
What speaks for TNYA
- First-in-class potential for TN-201
What speaks against TNYA
- Short Liquidity Runway (18 Months)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TNYA | n/a | 584.2x | n/a | 144.9% | -36891.1% | -49.2% |
| OKUR | n/a | 0.0x | 2.3x | 0.0% | 0.0% | -86.0% |
| EQ | n/a | 0.0x | n/a | 0.0% | 0.0% | -19.3% |
| HUMA | n/a | 53.7x | n/a | -748.5% | -4840.8% | -94.5% |
| NKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -51.3% |
| ALEC | n/a | 9.2x | n/a | -396.9% | -680.8% | -102.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -86.0% |
Frequently asked questions about Tenaya Therapeutics Inc (TNYA)
Is TNYA stock a good investment?
The cached TradeMates AI model rates Tenaya Therapeutics Inc as WATCH (do not buy) with an investment score of 42/100. Tenaya offers high-optionality on gene therapy for heart disease but faces binary clinical risks and a ticking clock on cash reserves. This is algorithmic model output, not personal investment advice.
Is TNYA stock a buy?
The TradeMates model verdict for TNYA is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.